References
- Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671–674.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.
- O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenousinhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285.
- Felbor U, Dreier L, Bryant RAR, Ploegh HL, Olsen BR, MothesW. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187–1194.
- Halfter W, Dong S, Schurer B, Cole GJ. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem, 1998; 273: 25404–25412.
- Dhanabal M, Ramchandran R, Waterman MJ et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721–11726.
- Lai R, Estey E, Shen Y et al. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer, 2002; 94: 14–17.
- Wrobel T, Mazur G, Kapelko K, Kuliczkowski K. Endostatin serum level in acute myeloid leukemia. Neoplasma 2005; 52:182–184.
- Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721.
- Hussong JW, Rodgers GM, Shami Pi. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 2000; 95: 309–313.
- Glenjen N, Mosevoll KA, Bruserud 0. Serum levels of angiogenin,basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer, 2003; 101: 86–94.
- Grimwade D, Walker H, Oliver Fet al. The importance of diagnosticcytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.
- Bertolini F, Paolucci M, Peccatori F et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504–509.
- Bertolini F, Fusetti L, Mancuso P et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemother-apy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96: 282–287.
- Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation 2003; 12: 167–171.
- Folkman J, Kalluri R. Cancer without disease. Nature, 2004; 427: 787–789.
- Kumar S, Witzig TE, Timm M et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood, 2004; 104: 1159–1165.
- Teh SH, Hill AD, Lee AW et al. Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res 2004; 116: 165–171.
- Bruserud O, Glenjen N, Ryningen A. Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts. Eur J Haematol 2003; 71: 9–17.
- Jung SP, Siegrist B, Hornick CA et al. Effect of human recombinant Endostatin protein on human angiogenesis. Angiogenesis, 2002; 5: 111–118.
- Schuch G, Heymach K, Nomi M et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003; 63: 8345–8350.
- Schuch G, Oliveira-Ferrer L, Loges S et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia, 2005; 19: 1312–1317.